Phase i dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 5, 2009, Pages 953-958

  Loibl, Sibylle ^a,b   Murmann, Caroline ^a,b   Schwedler, Katrin ^b   Warm, Mathias ^c   Müller, Lothar ^d   Heinrich, Georg ^e   Nekljudova, Valentina ^a   Von Minckwitz, Gunter ^a,b  

^a GBG Forschungs GmbH   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d Center for Hematology and Oncology   (Germany)

^e Outpatient Clinic for Gynaecological Oncology   (Germany)

Author keywords

Anthracycline free; Bendamustine; Breast cancer; Paclitaxel; Phase I

Indexed keywords

ANTHRACYCLINE; BENDAMUSTINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER GROWTH; CANCER REGRESSION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HOT FLUSH; HUMAN; HYPERBILIRUBINEMIA; HYPOCALCEMIA; INFECTION; INJECTION SITE REACTION; KIDNEY DISEASE; LEUKOPENIA; LIVER METASTASIS; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA; NEUROPATHY; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY DYSFUNCTION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NITROGEN MUSTARD COMPOUNDS; PACLITAXEL; PLEURAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 61449188314     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0821-8     Document Type: Article

References (18)

1. D Strumberg A Harstrick K Doll 1996 Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines Anticancer Drugs 7 415 421
2. LM Leoni B Bailey J Reifert 2008 Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents Clin Cancer Res 14 309 317
3. G von Minckwitz I Chernozemsky L Sirakova 2005 Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC Anticancer Drugs 16 871 877
4. U Reichmann C Bokemeyer D Wallwiener 2007 Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine Ann Oncol 18 1981 1984
5. K Hoffken K Merkle M Schonfelder 1998 Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study J Cancer Res Clin Oncol 124 627 632
6. MH Eichbaum F Schuetz T Khbeis 2007 Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study Anticancer Drugs 18 963 968
7. P Schoffski G Seeland H Engel 2000 Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours Ann Oncol 11 729 734
8. P Schoffski T Hagedorn V Grunwald 2000 Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours J Cancer Res Clin Oncol 126 41 47
9. EA Perez CL Vogel DH Irwin 2001 Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer J Clin Oncol 19 4216 4223
10. SN Goodman ML Zahurak S Piantadosi 1995 Some practical improvements in the continual reassessment method for phase I studies Stat Med 14 1149 1161
11. L Edler 1990 Statistical requirements of phase I studies Onkologie 13 90 95
12. AD Seidman D Berry C Cirrincione 2008 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 J Clin Oncol 26 1642 1649
13. M Pegram J Forbes T Pienkowski 2007 BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC) J Clin Oncol 25 968S (abstract LBA1008)
14. von Minckwitz G, Rezai M, Loibl S et al (2007) Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide- docetaxel as neoadjuvant treatment for primary breast cancer. In: First efficacy analysis of the GBG/AGO intergroup-study GeparQuattro. San Antonio Breast Cancer Symposium, San Antonio, TX, 2007 (abstract 79)
15. C Sessa O Pagani G Martinelli 1997 Dose-finding study of paclitaxel and cyclophosphamide in women with advanced breast cancer Semin Oncol 24 S17
16. EA Perez CL Vogel DH Irwin 2002 Weekly paclitaxel in women age 65 and above with metastatic breast cancer Breast Cancer Res Treat 73 85 88
17. AJ ten Tije CH Smorenburg C Seynaeve 2004 Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial Eur J Cancer 40 352 357
18. SE Jones MA Savin FA Holmes 2006 Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer J Clin Oncol 24 5381 5387